Although the use of thiazolidinediones in the treatment of type 2 diabetes is controversial, they still comprise an important class of insulin-sensitizing drugs. In two reports, new evidence emerges that these drugs rely on the activation of their target, PPAR-A, in the brain to improve hepatic insulin sensitivity and increase food intake and reduce energy expenditure.
- Karen K Ryan
- Bailing Li
- Randy J Seeley